CITIC Private Equity has made a partial exit from Chinese biotech player 3SBio as the company raised HK$5.51 billion ($711 million), two years after leaving NASDAQ in a take-private deal.
Exits | 08 Jun 2015 |
Fidelity Growth Partners India (FGPI) and affiliated US fund Fidelity Biosciences have invested $10 million in Medwell Ventures, operator of Nightingales specialty home healthcare services.
South Asia | 05 Jun 2015 |
A consortium of Chinese investors including Shanghai Fosun Pharmaceutical Group, Hopu Investments, CEL Healthcare Fund and WuXi PharmaTech will acquire Ambrx, a US-based biotech pharmaceutical developer.
Greater China | 22 May 2015 |
Hony Capital CEO John Zhao expects to see more control opportunities arising from domestic succession planning, cross-border expansion and restructuring. He explains how his firm is preparing the ground
Buyouts | 20 May 2015
Private equity investors see huge opportunities in China’s hospital space on the back of healthcare reforms. But valuations are high, doctors are in limited supply, and regulation can be a headache
Buyouts | 20 May 2015
BeiGene, a Chinese company that develops drugs to combat cancer, has raised RMB600 million ($97 million) in a funding round led by existing investors Hillhouse Capital and an undisclosed US-based life sciences-focused public investment fund.
Greater China | 14 May 2015 |
Taiwan-based biopharmaceutical company JHL Biotech has raised a $45 million Series C round, led by an unnamed investor. Existing backer Milestone Capital also participated, along with newcomers Sungent BioVenture and Liwick Investment Management.
Greater China | 14 May 2015 |
CLSA Capital Partners (CLSA CP) has invested RMB150 million ($24.5 million) in Coco Healthcare Products, a Chinese manufacturer of diapers for adults and babies. It plans to help the company boost its export business.
Greater China | 13 May 2015 |
South Korea-based Posco Capital and biopharmaceutical player Green Cross have led a $7.5 million round for Juventas Therapeutics, a clinical-stage biotech development company based in the US.
South Asia | 13 May 2015 |
Inner Mongolia FuRui Medical Science (FuRui) started out two decades ago as a pure-play drug manufacturer, but then it found its niche developing diagnostic equipment and treatment for liver disease. Looking to bring in overseas technology, it acquired...
Healthcare | 06 May 2015
WuXi PharmaTech, a China-based provider of contract R&D services to the global pharmaceutical sector, has received a take-private bid led by its founder and chairman and healthcare-focused PE firm Ally Bridge Group.
Buyouts | 04 May 2015 |
India's Fortis Healthcare will sell its Singapore-based diagnostics arm RadLink-Asia to Fullerton Healthcare Group for S$111 million ($83.5 million).
South Asia | 04 May 2015 |
Cathay Capital has led a EUR30 million ($33 million) round of funding for Echosens, a France-based diagnostic medical device manufacturer owned by China’s Inner Mongolia FuRui Medical Science.
Greater China | 30 Apr 2015 |
Yunfeng Capital, Shenzhen Cowin Capital, New Horizon Capital and Hunan Haijie Healthcare Investment have provided RMB200 million ($32 million) in Series B funding for Huakang Mobile Healthcare, a Chinese mobile healthcare app developer.
Greater China | 29 Apr 2015 |
China Cord Blood, a US-listed blood banking operator in which KKR holds a minority stake, has received a take-private offer from its largest shareholder, Chinese healthcare company Golden Meditech.
Exits | 29 Apr 2015 |
Updating your subscription status
The Australasian alternative assets industry is evolving and this is creating a new set of challenges for participants. Funds seeking new commitments typically require the lion share to be from offshore, the deal environment is competitive and in general market activity has slowed reflecting the regions overall macro-economic story. However, a handful of funds have had successful fundraises and it is clear that the GPs that measure up when benchmarked on a global stage will continue to drive the domestic industry forward.
This is an intriguing time as Australasian PE matures. Succession planning strategies, sourcing offshore commitments, creating a team that can deliver real operational value, customising the PE model and finding attractive investment and exit opportunities in a slow market are all key topics for debate.
Join over 300 attendees in Australia when industry leaders from across the globe meet for 2 days of high level debate and set the agenda on domestic, regional and global issues.
2-4 March 2016, The Westin Hotel, Sydney
Heading into its 15th consecutive year, the AVCJ China, Private Equity and Venture Forum, is built to be the premier gathering for the most influential private equity professionals, government officials, regulators, global investors and senior executives to meet for two days of mind-provoking debate, in-depth discussion on market trends, networking and more.
Join this annual signature event for the Private Equity and Venture Capital industry in Beijing. With over 300 leaders, from across the globe, converging to grasp the latest investment opportunities available, in the world's second largest economy.
9-10 March 2016, China World Summit Wing, Beijing